A Phase 2 interventional study of REGN910-3 and Intravitreal Aflibercept Injection (IAI) in Diabetic Macular Edema, sponsored by Regeneron Pharmaceuticals. Completed at 51 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-03.
Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies testing aflibercept in Macular Edema — 1 open to participants now, 3 under way, 1 of them phase 3. aflibercept · Macular Edema.
Among the 53 studies testing aflibercept in Macular Edema, this one is the 9th largest by enrollment, is one of 9 that started in 2016, is one of 7 in phase 2, and was the 29th registered.
758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.
Browse Macular Edema studies →1 of the 53 studies testing aflibercept in Macular Edema is open now, in 1 country. Recruiting first, the newest first:
CMH Multan Institute of Medical Sciences · Sites in Pakistan
Ages 30–60
By country, each count listing its studies:
aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9 · Phase 3 12 · Phase 4 26
First in 2006; this study’s year is marked. 9 started in 2016.
This study's enrollment of 302 is above the median of 56 across 586 interventional studies indexed under Macular Edema.
Median enrollment 49 across the 53 interventional studies. Of the 36 that completed or were terminated, 18 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 53 have an industry lead sponsor. The 10 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Regeneron Pharmaceuticals has 7 studies filed under Macular Edema — fewer than ten, so there is no comparison to draw.
1 of the studies testing aflibercept in Macular Edema that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02645266McMaster UniversityMean Visual Acuity Changes Following Five Injections of Aflibercept | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 53 studies testing aflibercept in Macular Edema, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of the study was to compare the efficacy of intravitreal (IVT)-administered REGN910-3 compared to intravitreal aflibercept injection (IAI) in improving best corrected visual acuity (BCVA) in participants with diabetic macular edema (DME).
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other inclusion/ exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants were administered intravitreal injection of REGN910-3 (3 milligram (mg):2 mg) every 4 weeks (Q4) on Day 1, Week 4, and Week 8 for 3 initial doses followed by every Week 8 (Q8) dosing beginning at Week 16 up to Week 32.
Drug: REGN910-3
Participants were administered intravitreal injection of REGN910-3 (6 mg:2 mg) Q4 on Day 1, Week 4 and Week 8 for 3 initial doses up to week 12.
Drug: REGN910-3
Participants were administered intravitreal injection of Aflibercept (IAI) 2 mg Q4 on Day 1, Week 4 and Week 8 for 3 initial doses up to Week 12.
Drug: Intravitreal Aflibercept Injection (IAI)
Participants were administered intravitreal injection of REGN910-3 (6 mg:2 mg) Q4 on Day 1, Week 4 and Week 8 for 3 initial doses. At Week 12, participants were re-randomized to receive REGN910-3 (6 mg:2 mg) at Week 16 and Q8 through Week 32.
Drug: REGN910-3
Participants were administered intravitreal injection of REGN910-3 (6 mg:2 mg) Q4 on Day 1, Week 4 and Week 8 for 3 initial doses. At week 12, participants were re-randomized to receive REGN910-3 (6 mg:2 mg) at Week 20 and Q12 through Week 32.
Drug: REGN910-3
Participants were administered intravitreal injection of Aflibercept (IAI) 2 mg Q4 on Day 1, Week 4 and Week 8 for 3 initial doses up to Week 12. At Week 12, participants were re-randomized to receive IAI at Week16 and Q8 through Week 32.
Drug: Intravitreal Aflibercept Injection (IAI)
Participants were administered intravitreal injection of Aflibercept (IAI) 2 mg Q4 on Day 1, Week 4 and Week 8 for 3 initial doses up to Week 12. At Week 12, participants were re-randomized to receive IAI at Week 20 and Q12 through Week 32.
Drug: Intravitreal Aflibercept Injection (IAI)
Participants were administered intravitreal injection of Aflibercept (IAI) 2 mg Q4 on Day 1, Week 4 and Week 8 for 3 initial doses up to Week 12. At week 12, participants were re-randomized to receive REGN910-3 (6 mg:2 mg) at week 16 and Q8 through week 32.
Drug: REGN910-3 · Drug: Intravitreal Aflibercept Injection (IAI)
Co-formulation for intravitreal (IVT) injection consisting of REGN910 (nesvacumab) and REGN3 (aflibercept)
Also known as: EYLEA® (aflibercept) Injection, BAY86-5321
Change From Baseline in Best Corrected Visual Acuity (BCVA) Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 12
Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol at 4 meters. Best Corrected Visual Acuity (BCVA) score was measured using an eye chart and was reported as the number of letters read correctly at a testing distance of 4 meters using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. Change from baseline calculated by subtracting baseline value from observed post-baseline value at Week 12.
Time frame: Baseline, Week 12
Change From Baseline in Best Corrected Visual Acuity (BCVA) Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 36
Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol at 4 meters. BCVA score was measured using an eye chart and was reported as the number of letters read correctly at a testing distance of 4 meters using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. Change from baseline calculated by subtracting baseline value from observed post-baseline value at Week 36.
Time frame: Baseline, Week 36
Change From Baseline in Central Sub-field Retinal Thickness (CST) Measured by Spectral Domain Optical Coherence Tomography (SD-OCT) at Week 12
Central Sub-field Retinal Thickness (CST) was assessed using Spectral Domain Optical Coherence Tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation. A negative change from baseline indicated improvement. Change from baseline calculated by subtracting baseline value from LOCF post-baseline value at Week 12.
Time frame: Baseline, Week 12
Change From Baseline in Central Sub-field Retinal Thickness (CST) Measured by Spectral Domain Optical Coherence Tomography (SD-OCT) at Week 36
CST was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation. A negative change from baseline indicated improvement. Change from baseline calculated by subtracting baseline value from LOCF post-baseline value at Week 36.
Time frame: Baseline, Week 36
Percentage of Participants With a ≥ 2-step Improvement at Week 12 in Diabetic Retinopathy Severity Scale (DRSS) From Baseline
The Diabetic Retinopathy Disease Severity Scale (DRSS) was used to describe overall retinopathy severity. It measured the 5 levels of diabetic retinopathy ranging from absence of retinopathy to severe retinopathy (none, mild, moderate, severe, and proliferative).
Time frame: Baseline, Week 12
Percentage of Participants With a ≥ 2-step Improvement at Week 36 in Diabetic Retinopathy Severity Scale (DRSS) From Baseline
The Diabetic Retinopathy Disease Severity Scale (DRSS) was used to describe overall retinopathy severity. It measured the 5 levels of diabetic retinopathy ranging from absence of retinopathy to severe retinopathy (none, mild, moderate, severe, and proliferative).
Time frame: Baseline, Week 36
The study was conducted at 70 sites in US. A total of 438 participants were screened in the study.
| Milestone | REGN910-3 (3 mg: 2 mg) | REGN910-3 (6 mg:2 mg) | Aflibercept 2 mg | REGN910-3 (6 mg:2 mg) Q4 to REGN910-3 (6 mg:2 mg) Q8 | REGN910-3 (6 mg:2 mg) Q4 to REGN910-3 (6 mg:2 mg) Q12 | Aflibercept 2 mg Q4 to Aflibercept 2 mg Q8 | Aflibercept 2 mg Q4 to Aflibercept 2 mg Q12 | Aflibercept 2 mg Q4 to REGN910-3 (6 mg:2 mg) Q8 |
|---|---|---|---|---|---|---|---|---|
| Started | 50 | 100 | 152 | 0 | 0 | 0 | 0 | 0 |
| Completed | 46 | 97 | 148 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 4 | 3 | 4 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other unspecified | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | REGN910-3 (3 mg: 2 mg) | REGN910-3 (6 mg:2 mg) | Aflibercept 2 mg | REGN910-3 (6 mg:2 mg) Q4 to REGN910-3 (6 mg:2 mg) Q8 | REGN910-3 (6 mg:2 mg) Q4 to REGN910-3 (6 mg:2 mg) Q12 | Aflibercept 2 mg Q4 to Aflibercept 2 mg Q8 | Aflibercept 2 mg Q4 to Aflibercept 2 mg Q12 | Aflibercept 2 mg Q4 to REGN910-3 (6 mg:2 mg) Q8 |
|---|---|---|---|---|---|---|---|---|
| Started | 45 | 0 | 0 | 44 | 52 | 46 | 48 | 49 |
| Completed | 44 | 0 | 0 | 42 | 50 | 46 | 43 | 45 |
| Not completed | 1 | 0 | 0 | 2 | 2 | 0 | 5 | 4 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 2 |
| Withdrew: Death | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 2 |
Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol at 4 meters. Best Corrected Visual Acuity (BCVA) score was measured using an eye chart and was reported as the number of letters read correctly at a testing distance of 4 meters using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. Change from baseline calculated by subtracting baseline value from observed post-baseline value at Week 12.
| Letters correctly read | REGN910-3 (3 mg: 2 mg) | REGN910-3 (6 mg:2 mg) | Aflibercept 2 mg |
|---|---|---|---|
| Change From Baseline in Best Corrected Visual Acuity (BCVA) Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 12 | 6.8 ± 7.30 | 8.5 ± 6.89 | 8.8 ± 9.71 |
Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol at 4 meters. BCVA score was measured using an eye chart and was reported as the number of letters read correctly at a testing distance of 4 meters using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. Change from baseline calculated by subtracting baseline value from observed post-baseline value at Week 36.
| Letters correctly read | REGN910-3 (3 mg: 2 mg) | REGN910-3 (6 mg:2 mg) Q4 to REGN910-3 (6 mg:2 mg) Q8 | REGN910-3 (6 mg:2 mg) Q4 to REGN910-3 (6 mg:2 mg) Q12 | Aflibercept 2 mg Q4 to Aflibercept 2 mg Q8 | Aflibercept 2 mg Q4 to Aflibercept 2 mg Q12 | Aflibercept 2 mg Q4 to REGN910-3 (6 mg:2 mg) Q8 |
|---|---|---|---|---|---|---|
| Change From Baseline in Best Corrected Visual Acuity (BCVA) Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 36 | 9.8 ± 9.92 | 10.3 ± 8.20 | 8.5 ± 7.74 | 8.7 ± 10.65 | 10.0 ± 10.37 | 11.9 ± 12.01 |
Central Sub-field Retinal Thickness (CST) was assessed using Spectral Domain Optical Coherence Tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation. A negative change from baseline indicated improvement. Change from baseline calculated by subtracting baseline value from LOCF post-baseline value at Week 12.
| Microns | REGN910-3 (3 mg: 2 mg) | REGN910-3 (6 mg:2 mg) | Aflibercept 2 mg |
|---|---|---|---|
| Change From Baseline in Central Sub-field Retinal Thickness (CST) Measured by Spectral Domain Optical Coherence Tomography (SD-OCT) at Week 12 | -169.4 ± 155.86 | -184.0 ± 143.69 | -174.6 ± 160.36 |
CST was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation. A negative change from baseline indicated improvement. Change from baseline calculated by subtracting baseline value from LOCF post-baseline value at Week 36.
| Microns | REGN910-3 (3 mg: 2 mg) | REGN910-3 (6 mg:2 mg) Q4 to REGN910-3 (6 mg:2 mg) Q8 | REGN910-3 (6 mg:2 mg) Q4 to REGN910-3 (6 mg:2 mg) Q12 | Aflibercept 2 mg Q4 to Aflibercept 2 mg Q8 | Aflibercept 2 mg Q4 to Aflibercept 2 mg Q12 | Aflibercept 2 mg Q4 to REGN910-3 (6 mg:2 mg) Q8 |
|---|---|---|---|---|---|---|
| Change From Baseline in Central Sub-field Retinal Thickness (CST) Measured by Spectral Domain Optical Coherence Tomography (SD-OCT) at Week 36 | -210.4 ± 164.06 | -223.4 ± 145.35 | -193.7 ± 158.29 | -161.9 ± 125.99 | -210.6 ± 202.15 | -203.7 ± 163.08 |
The Diabetic Retinopathy Disease Severity Scale (DRSS) was used to describe overall retinopathy severity. It measured the 5 levels of diabetic retinopathy ranging from absence of retinopathy to severe retinopathy (none, mild, moderate, severe, and proliferative).
| Percentage of participants | REGN910-3 (3 mg: 2 mg) | REGN910-3 (6 mg:2 mg) | Aflibercept 2 mg |
|---|---|---|---|
| Percentage of Participants With a ≥ 2-step Improvement at Week 12 in Diabetic Retinopathy Severity Scale (DRSS) From Baseline | 13.3 | 21.3 | 15.2 |
The Diabetic Retinopathy Disease Severity Scale (DRSS) was used to describe overall retinopathy severity. It measured the 5 levels of diabetic retinopathy ranging from absence of retinopathy to severe retinopathy (none, mild, moderate, severe, and proliferative).
| Percentage of participants | REGN910-3 (3 mg: 2 mg) | REGN910-3 (6 mg:2 mg) Q4 to REGN910-3 (6 mg:2 mg) Q8 | REGN910-3 (6 mg:2 mg) Q4 to REGN910-3 (6 mg:2 mg) Q12 | Aflibercept 2 mg Q4 to Aflibercept 2 mg Q8 | Aflibercept 2 mg Q4 to Aflibercept 2 mg Q12 | Aflibercept 2 mg Q4 to REGN910-3 (6 mg:2 mg) Q8 |
|---|---|---|---|---|---|---|
| Percentage of Participants With a ≥ 2-step Improvement at Week 36 in Diabetic Retinopathy Severity Scale (DRSS) From Baseline | 26.7 | 34.1 | 34.0 | 26.1 | 25.5 | 35.4 |
Collected over All Adverse Events (AE) were collected from signature of the informed consent form up to the final visit (Week 36) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| REGN910-3 (3 mg: 2 mg) | 5/50 (10%) | 6/50 (12%) | 18/50 (36%) |
| REGN910-3 (6 mg:2 mg) | 0/100 (0%) | 18/100 (18%) | 42/100 (42%) |
| Aflibercept 2 mg | 4/152 (2.6%) | 31/152 (20.4%) | 55/152 (36.2%) |
| Event | REGN910-3 (3 mg: 2 mg) | REGN910-3 (6 mg:2 mg) | Aflibercept 2 mg |
|---|---|---|---|
| DeathGeneral disorders | 2/50 | 0/100 | 0/152 |
| Cardiac failure congestiveCardiac disorders | 0/50 | 3/100 | 3/152 |
| Cardiac arrestCardiac disorders | 1/50 | 0/100 | 0/152 |
| CellulitisInfections and infestations | 1/50 | 1/100 | 3/152 |
| Diabetic foot infectionInfections and infestations | 1/50 | 0/100 | 0/152 |
| OsteomyelitisInfections and infestations | 1/50 | 1/100 | 1/152 |
| FallInjury, poisoning and procedural complications | 0/50 | 2/100 | 1/152 |
| Troponin increasedInvestigations | 1/50 | 0/100 | 0/152 |
| Cerebrovascular accidentNervous system disorders | 1/50 | 0/100 | 0/152 |
| Diabetic footSkin and subcutaneous tissue disorders | 1/50 | 0/100 | 2/152 |
| Event | REGN910-3 (3 mg: 2 mg) | REGN910-3 (6 mg:2 mg) | Aflibercept 2 mg |
|---|---|---|---|
| HypertensionVascular disorders | 4/50 | 14/100 | 19/152 |
| Conjunctival haemorrhageEye disorders | 5/50 | 3/100 | 13/152 |
| Vitreous detachmentEye disorders | 1/50 | 8/100 | 8/152 |
| Blood pressure increasedInvestigations | 2/50 | 7/100 | 10/152 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/50 | 7/100 | 4/152 |
| Eye painEye disorders | 3/50 | 3/100 | 4/152 |
| Viral upper respiratory tract infectionInfections and infestations | 3/50 | 3/100 | 5/152 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 3/50 | 0/100 | 1/152 |
| Neuropathy peripheralNervous system disorders | 3/50 | 0/100 | 0/152 |
| Dry eyeEye disorders | 0/50 | 5/100 | 1/152 |
| Age, Continuous(years) | REGN910-3 (3 mg: 2 mg) | REGN910-3 (6 mg:2 mg) | Aflibercept 2 mg | Total |
|---|---|---|---|---|
| Mean | 62.5 ± 9.12 | 62.5 ± 10.36 | 59.5 ± 10.20 | 61.0 ± 10.16 |
| Sex: Female, Male(Participants) | REGN910-3 (3 mg: 2 mg) | REGN910-3 (6 mg:2 mg) | Aflibercept 2 mg | Total |
|---|---|---|---|---|
| Female | 21 | 49 | 68 | 138 |
| Male | 29 | 51 | 84 | 164 |
| Ethnicity (NIH/OMB)(Participants) | REGN910-3 (3 mg: 2 mg) | REGN910-3 (6 mg:2 mg) | Aflibercept 2 mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 6 | 21 | 26 | 53 |
| Not Hispanic or Latino | 44 | 78 | 125 | 247 |
| Unknown or Not Reported | 0 | 1 | 1 | 2 |
| Race (NIH/OMB)(Participants) | REGN910-3 (3 mg: 2 mg) | REGN910-3 (6 mg:2 mg) | Aflibercept 2 mg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 3 | 4 |
| Asian | 1 | 2 | 4 | 7 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 1 |
| Black or African American | 11 | 8 | 19 | 38 |
| White | 37 | 87 | 121 | 245 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 2 | 5 | 7 |
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Mar 2016, a primary completion of Jul 2017 and a completion of Jul 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2018, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: REGN910-3 · Aflibercept